Biocept announces that it will begin commercializing its recently expanded pathology partnership platform, EmpowerTC, to urology and uropathology practices. Biocept has expanded the capability of EmpowerTC to perform biomarker tests that can aid physicians and pathologists in the management of patients diagnosed with prostate cancer. Such tests include the androgen receptor splice variant, AR-V7, PTEN, and other cancer biomarker tests, which can help physicians determine treatment pathways and provide prognostic information with regards to aggressiveness of disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.